SEC Form 4 · accession 0001209191-17-017516
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Cole
Officer — Chief Legal Officer
Period of report
Mar 1, 2017
Accepted (ET)
Mar 3, 2017 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2017 | M | 5,225 | $50.51 | A | 17,276 | D | |
| Common StockF2 | Mar 1, 2017 | S | 5,225 | $90.3179 | D | 12,051 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $50.51 | Mar 1, 2017 | M | 5,225 | D | — | Mar 1, 2026 | Common Stock | 5,225 | 15,675 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
- F2The range in prices for the transaction reported on this line was $90.00 to $90.65. The average weighted price was $90.3179. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.